Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

Amyotrophic Lateral Sclerosis. Recent Advances In Pathogenesis And Therapeutic Trials.

H. Mitsumoto, M. Hanson, D. Chad
Published 1988 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
We reviewed the current status of pathogenesis and therapeutic trials in amyotrophic lateral sclerosis (ALS). Clinical studies have identified several rare but definable causes for apparent ALS. Certain clinical features previously considered unlikely to occur in ALS are found on careful examination. Epidemiologic surveillance and recent studies of neurotoxic plant seeds used in Guam have shed light on the pathogenesis of endemic ALS. Extensive analyses of biochemical, metabolic, immunologic, viral, and toxic factors have provided provocative results requiring further studies. Reflecting on some of these hypotheses, therapeutic trials have been performed more vigorously than ever. Amyotrophic lateral sclerosis is now investigated at the molecular genetic level. Human autopsy and experimental animal studies have expanded our understanding of basic mechanisms involving motoneuronal degeneration. In the future, we must continue a relentless search for the pathogenesis of ALS, prospective clinical studies to define the limits of ALS, and well-designed, controlled therapeutic trials.
This paper references
10.1212/WNL.35.2.193
Disappearance of high‐incidence amyotrophic lateral sclerosis and parkinsonism‐dementia on Guam
R. Garruto (1985)
DNA hypothesis of amyotrophic lateral sclerosis.
W. G. Bradley (1982)
10.1001/ARCHNEUR.1974.00490370044005
Reversible forms of motor neuron disease. Lead "neuritis".
J. A. Boothby (1974)
10.1001/ARCHNEUR.1986.00520040063021
Failure of immunosuppression with a ten- to 14-day course of high-dose intravenous cyclophosphamide to alter the progression of amyotrophic lateral sclerosis.
R. Brown (1986)
10.1001/ARCHNEUR.1982.00510160047010
Thyroid function in 44 patients with amyotrophic lateral sclerosis.
W. R. Kiessling (1982)
10.1016/S0733-8619(18)30939-3
Intravenous thyrotropin-releasing hormone in patients with amyotrophic lateral sclerosis. Dose-response and randomized concurrent placebo-controlled pilot studies.
B. Brooks (1987)
10.1212/WNL.33.2.254
Anticoagulation and embolic infarction
A. Furlan (1983)
10.1001/ARCHNEUR.1974.00490370081013
Hypothalamic releasing factors and Parkinson disease.
T. Chase (1974)
10.1002/ANA.410130117
Epidemiological surveillance of amyotrophic lateral sclerosis and parkinsonism‐dementia in the commonwealth of the Northern Mariana Islands
R. Yanagihara (1983)
10.1002/ANA.410100602
A unifying hypothesis for the cause of amyotrophic lateral sclerosis, parkinsonism, and alzheimer disease
S. Appel (1981)
10.1002/MUS.880040303
Therapeutic trials in neuromuscular diseases
W. Bradley (1981)
10.1126/SCIENCE.867053
Androgen concentration in motor neurons of cranial nerves and spinal cord.
M. Sar (1977)
10.1056/NEJM198707023170102
Late denervation in patients with antecedent paralytic poliomyelitis.
N. Cashman (1987)
10.1136/jnnp.31.6.535
An hereditary motor neurone disease with progressive denervation of muscle in the mouse: the mutant 'wobbler'.
L. Duchen (1968)
10.1016/0165-5728(84)90042-0
Deposits of IgG and C3 in the spinal cord and motor cortex of ALS patients
H. Donnenfeld (1984)
10.1016/0022-510X(85)90113-3
Heavy metal concentrations in blood cells in patients with amyotrophic lateral sclerosis
Hiroshi Nagata (1985)
10.1016/S0140-6736(73)92735-9
Motoneurone disease and ageing.
A. McComas (1973)
[Oculomotor abnormalities in amyotrophic lateral sclerosis].
F. Yoshii (1984)
10.1212/WNL.33.2.202
Osteosclerotic myeloma and peripheral neuropathy
J. Kelly (1983)
10.1016/0022-510X(86)90175-9
Concentrations of thyrotropin-releasing hormone in the brain of patients with amyotrophic lateral sclerosis
T. Mitsuma (1986)
10.1056/NEJM198312013092216
Amyotrophic lateral sclerosis and pet exposure.
D. Mulder (1983)
10.1136/jnnp.47.9.953
Presenile dementia with motor neuron disease in Japan: clinico-pathological review of 26 cases.
Y. Mitsuyama (1984)
10.1001/ARCHNEUR.1980.00500520027002
Possible role of androgen receptors in amyotrophic lateral sclerosis. A hypothesis.
L. Weiner (1980)
Motor neuron disease and toxic metals.
S. Conradi (1982)
[Sensory disturbances in amyotrophic lateral sclerosis].
K. Tashiro (1984)
10.1515/9783111510828-078
The significance of vitamin B12 binders in the central nervous system
M. Inada (1979)
10.1002/ANA.410180311
Detection of picornavirus sequences in nervous tissue of amyotrophic lateral sclerosis and control patients
M. Brahic (1985)
10.1016/0165-5728(86)90034-2
An immune-mediated guinea pig model for lower motor neuron disease
J. Engelhardt (1986)
10.1001/ARCHNEUR.1984.04210080062015
Plasma exchange in neurologic diseases.
R. Lisak (1984)
10.1016/0006-8993(82)90081-6
Regional distribution of cholinergic neurons in human spinal cord transections in the patients with and without motor neurons disease
Y. Nagata (1982)
10.1001/ARCHNEUR.1969.00480140021002
Hypoglycemic peripheral neuropathy.
G. Danta (1969)
Patient resistance and prognosis in amyotrophic lateral sclerosis.
Mulder Dw (1976)
10.1056/NEJM198110293051806
Thyrotropin-Releasing Hormone Improves Neurologic Recovery after Spinal Trauma in Cats
A. Faden (1981)
10.1002/JNR.490120209
Gangliosides of human spinal cord: Aberrant composition of cords from patients with amyotrophic lateral sclerosis
G. Dawson (1984)
10.1016/0022-510X(84)90199-0
Neurofibrillary axonal swellings and amyotrophic lateral sclerosis
M. Delisle (1984)
10.1016/S0140-6736(72)92903-0
The pathogenesis of amyotrophic lateral sclerosis.
Y. Yase (1972)
10.1212/WNL.35.5.717
ALS and pet exposure
S. Tarras (1985)
10.1002/ANA.410080625
Plasmapheresis in amyotrophic lateral sclerosis
M. Olarte (1980)
10.1212/WNL.35.1.108
Long‐acting propranolol in essential tremor
W. Koller (1985)
10.1001/ARCHNEUR.1986.00520040026013
Abnormalities of multimodality evoked potentials in amyotrophic lateral sclerosis.
J. Matheson (1986)
Research progress in motor neuron diseases.
Rowland Lp (1988)
10.1001/ARCHNEUR.1984.04050220085023
Lipofuscin in amyotrophic lateral sclerosis.
G. McHolm (1984)
Are motor neuropathies and motor neuron diseases separable?
P. Dyck (1982)
Lead content of cerebrospinal fluid and other tissue in amyotrophic lateral sclerosis (ALS)
W. Manton (1979)
10.1002/ANA.410180402
Amyotrophic leteral sclerosis: Part 2. Etiopathogenesis
R. Tandan (1985)
10.1097/00005072-198103000-00009
RNA Content and Volume of Motor Neurons in Amyotrophic Lateral Sclerosis: II. The Lumbar Intumescence and Nucleus Dorsalis
T. J. Davidson (1981)
10.1002/ANA.410050310
Subacute motor neuronopathy: A Remote effect of lymphoma
S. Schold (1979)
10.1001/JAMA.1975.03260200031014
Symptomatic care of patients with amyotrophic lateral sclerosis.
R. A. Smith (1975)
10.1002/ANA.410100210
Humoral immunity in guamanians with amyotrophic lateral sclerosis and parkinsonism‐dementia
P. Hoffman (1981)
10.1212/WNL.33.7.911
Geographic distribution of motor neuron disease and correlation with possible etiologic factors
N. Bharucha (1983)
10.1001/ARCHNEUR.1979.00500450054009
Histologic findings in motor neuron disease. Relation to clinically determined activity, duration, and severity of disease.
B. Patten (1979)
10.1001/ARCHNEUR.1967.00470210008002
Familial amyotrophic lateral sclerosis. A subgroup characterized by posterior and spinocerebellar tract involvement and hyaline inclusions in the anterior horn cells.
A. Hirano (1967)
10.1002/MUS.880050109
Neuron specific in vitro cytotoxicity of sera from patients with amyotrophic lateral sclerosis
F. Roisen (1982)
10.1016/0022-510X(83)90051-5
Lead concentrations in blood, plasma, erythrocytes, and cerebrospinal fluid in amyotrophic lateral sclerosis
T. Stober (1983)
10.1016/0022-510X(83)90006-0
A therapeutic trial of gangliosides and thymosin in the wobbler mouse model of motor neuron disease
D. Lange (1983)
10.1002/ANA.410040419
Amyotrophic lateral sclerosis sera are not cytotoxic to neuroblastoma cells in tissue culture
J. Lehrich (1978)
10.1016/0022-510X(80)90112-4
Abnormal distribution of lead in amyotrophic lateral sclerosis: Reestimation of lead in the cerebrospinal fluid
S. Conradi (1980)
10.1136/jnnp.49.7.817
Sera from patients with motor neuron disease and associated paraproteinaemia fail to inhibit experimentally induced sprouting of motor nerve terminals.
M. Donaghy (1986)
10.1016/S0165-5728(85)80013-8
Immunoregulatory and activated T cells in amyotrophic lateral sclerosis patients
H. Bartfeld (1985)
10.1111/j.1600-0404.1984.tb00802.x
Neuropathy and motor neuron syndromes associated with plasma cell disease
B. Patten (1984)
10.1016/0022-510X(82)90082-X
Longitudinal spinal cord sections as substratum for anti-neurofilament antibody detection
S. Bahmanyar (1982)
10.1111/J.1600-0404.1984.TB02429.X
Interferon treatment in amyotrophic lateral sclerosis
M. Färkkilä (1984)
10.1016/0304-3940(75)90028-2
Thyrotropin releasing hormone (TRH)-containing nerve terminals in certain brain stem nuclei and in the spinal cord
T. Hökfelt (1975)
10.1016/0006-8993(77)90471-1
Thyrotropin-releasing hormone (TRH) in rat spinal cord
F. Kardon (1977)
10.1002/ANA.410150704
Emission tomographic measurement of local cerebral blood flow in humans by an in vivo autoradiographic strategy
M. Ginsberg (1984)
10.1002/MUS.880040108
Plasma and red blood cell acetylcholinesterase in amyotrophic lateral sclerosis
B. Festoff (1981)
10.1002/ANA.410140104
Syndromes of amyotrophic lateral sclerosis and dementia: Relation to transmissible Creutzfeldt‐Jakob disease
A. Salazar (1983)
10.1002/MUS.880040610
Late changes in the motor unit after acute poliomyelitis
D. Wiechers (1981)
10.1212/WNL.37.1.152
Antineural antibodies in the serum of patients with amyotrophic lateral sclerosis
R. Brown (1987)
10.1212/WNL.34.3.393
ALS and heavy metals
R. A. Roelofs-Iverson (1984)
10.1212/WNL.37.4.715
Treatment of amyotrophic lateral sclerosis with the TRH analog DN‐1417
R. J. Hawley (1987)
10.1016/0022-510X(82)90118-6
Further studies on the erythrocyte uptake of lead in vitro in amyotrophic lateral sclerosis (ALS) patients and controls: Abnormal eythrocyte fragility in ALS
L. Ronnevi (1982)
10.1097/00005072-197501000-00002
THE FINE STRUCTURE OF THE CERVICAL SPINAL CORD, VENTRAL ROOT AND BRACHIAL NERVES IN THE WOBBLER (wr) MOUSE
J. Andrews (1975)
10.1016/0022-510X(86)90130-9
Shy-Drager syndrome and amyotrophic lateral sclerosis: Cytoarchitectonic and morphometric studies of sacral autonomic neurons
H. Konno (1986)
10.1212/WNL.10.8.717
A cutaneous disorder of connective tissue in amyotrophic lateral sclerosis
H. Fullmer (1960)
10.1212/WNL.34.4.486
Poliovirus infection of cyclophosphamide‐ treated mice results in persistence and late paralysis
B. Jubelt (1984)
10.1001/ARCHNEUR.1986.00520030026007
Amyotrophic lateral sclerosis. Associated clinical disorders and immunological evaluations.
S. Appel (1986)
10.1001/ARCHNEUR.1984.04210080055014
Plasmapheresis. Therapeutic or experimental procedure?
P. Dau (1984)
10.1002/ANA.410090313
Reduced glycine receptor in the spinal cord in amyotrophic lateral sclerosis
H. Hayashi (1981)
10.1097/00005072-198405000-00004
Neurofilamentous Axonal Swellings as a Normal Finding in the Spinal Anterior Horn of Man and Other Primates
A. Clark (1984)
10.1212/WNL.36.4.454
Gangliosides GM1 and GD1b are antigens for IgM M-protein in a patient with motor neuron disease
L. Freddo (1986)
10.1212/WNL.31.10.1282
An eye movement disorder in amyotrophic lateral sclerosis
L. Jacobs (1981)
10.1001/ARCHNEUR.1982.00510190072029
Calcium content of RBCs from patients with amyotrophic lateral sclerosis.
M. Felmus (1982)
Studies on the pathogenesis of ALS with a review of the literature.
T. Mozai (1984)
Human motor neuron diseases.
L. Rowland (1982)
10.1016/0022-510X(84)90051-0
DNA damage and chronic neuronal degenerations
S. Robison (1984)
10.1001/ARCHNEUR.1982.00510230047014
Response of patients with amyotrophic lateral sclerosis to testosterone therapy: endocrine evaluation.
T. M. Jones (1982)
10.1002/ANA.410150411
Autosomal dominant inheritance of hereditary canine spinal muscular atrophy
G. Sack (1984)
10.1056/NEJM198410113111501
Inhibition of terminal axonal sprouting by serum from patients with amyotrophic lateral sclerosis.
M. Gurney (1984)
10.1212/WNL.34.8.1083
Ganglioside therapy for amyotrophic lateral sclerosis
H. Harrington (1984)
10.1111/j.1600-0404.1985.tb00874.x
Cholinergic, opioid and glycine receptor binding sites localized in human spinal cord by in vitro autoradiography Changes in amyotrophic lateral sclerosis
P. G. Gillberg (1985)
10.1212/WNL.30.5.463
ALS in Rochester, Minnesota, 1925–1977
S. Jürgens (1980)
Carcinomatous amyotrophic lateral sclerosis
F. Norris (1965)
Plasma cell dyscrasia and motor neuron disease.
N. Latov (1982)
10.1002/ANA.410180302
Amyotrophic lateral sclerosis: Part 1. Clinical features, pathology, and ethical issues in management
R. Tandan (1985)
10.1002/ANA.410140103
Amyotrophic lateral sclerosis: Alterations in neurotransmitter receptors
P. Whitehouse (1983)
10.1136/jnnp.47.12.1332
Amyotrophic lateral sclerosis: a double-blind crossover trial of thyrotropin-releasing hormone.
K. Imoto (1984)
10.1212/WNL.36.2.141
A double‐blind, placebo‐controlled trial of TRH in amyotrophic lateral sclerosis
J. Caroscio (1986)
10.1002/ANA.410170413
Motor neuron disease and adult hexosaminidase a deficiency in two families: Evidence for multisystem degeneration
H. Mitsumoto (1985)
10.1212/WNL.36.9.1218
Amyotrophic lateral sclerosis
I. Jackson (1986)
10.1212/WNL.25.8.781
Frequency of nerve fiber degeneration of peripheral motor and sensory neurons in amyotrophic lateral sclerosis
P. J. Dyck (1975)
10.1212/WNL.32.5.550
Skeletal muscle catabolism in amyotrophic lateral sclerosis and chronic spinal muscular atrophy
A. Corbett (1982)
[Treatment of amyotrophic lateral sclerosis with thyrotropin releasing hormone].
G. Serratrice (1986)
10.1136/jnnp.35.1.60
Spinal motor neurones in murine muscular dystrophy and spinal muscular atrophy
T. Papapetropoulos (1972)
10.1001/ARCHNEUR.1982.00510230010003
Eye movements in amyotrophic lateral sclerosis.
A. Léveillé (1982)
10.1212/WNL.4.6.438
Epidemiologic Investigations of Amyotrophic Lateral Sclerosis
L. Kurland (1954)
10.1002/ANA.410160306
Dementia and motor neuron disease: Morphometric, biochemical, and Golgi studies
D. S. Horoupian (1984)
10.1016/0022-510X(86)90035-3
Collagenase activity in skin fibroblasts of patients with amyotrophic lateral sclerosis
R. Beach (1986)
10.1002/ANA.410150108
Calcium and vitamin D metabolism in guamanian chamorros with amyotrophic lateral sclerosis and parkinsonism–dementia
R. Yanagihara (1984)
10.1001/ARCHNEUR.1982.00510210065018
A cluster of amyotrophic lateral sclerosis.
C. Melmed (1982)
10.1111/J.1600-0404.1980.TB03022.X
Cholinesterase activity of whole blood and plasma in amyotrophic lateral sclerosis
S. Conradi (1980)
10.1001/ARCHNEUR.1987.00520130079022
Hepatic ultrastructural changes and liver dysfunction in amyotrophic lateral sclerosis.
Y. Nakano (1987)
Late progression of poliomyelitis or forme fruste amyotrophic lateral sclerosis
Mulder Dw (1972)
10.1002/ANA.410190108
Impaired slow axonal transport in wobbler mouse motor neuron disease
H. Mitsumoto (1986)
10.1212/wnl.31.12.1581-a
Diagnosis and Treatment of Amyotrophic Lateral Sclerosis
D. Mulder (1981)
10.1097/00005072-198205000-00096
AXONAL TRANSPORT IN HEREDITARY CANINE SPINAL MUSCULAR ATROPHY (HCSMA): 88
J. W. Griffin (1982)
Cancer and the Nervous System: The Neurological Manifestations of Systemic Malignant Disease
R. A. Henson (1982)
10.1001/ARCHNEUR.1984.04050140059024
Passive transfer experiments in amyotrophic lateral sclerosis.
E. H. Denys (1984)
10.7326/0003-4819-80-2-182
Neuromuscular disease in primary hyperparathyroidism.
B. Patten (1974)
10.1212/WNL.30.8.884
Amyotrophic lateral sclerosis
J. R. Miller (1980)
10.1212/WNL.31.9.1196
CSF from amyotrophic lateral sclerosis patients applied to motor neurons in culture fails to alter neuron‐specific enolase
V. Askanas (1981)
10.1212/WNL.36.11.1429
Motor neuron disease and plasma cell dyscrasia
M. Shy (1986)
10.1016/0022-510X(83)90008-4
Controlled trial of thyrotropin releasing hormone tartrate in ataxia of spinocerebellar degenerations
I. Sobue (1983)
10.1016/0022-510X(76)90175-1
Abnormal tissue distribution of lead in amyotrophic lateral sclerosis
S. Conradi (1976)
10.1002/MUS.880090504
Skeletal muscle acetylcholinesterase molecular forms in amyotrophic lateral sclerosis
H. Fernández (1986)
Axonal transport in motor neuron pathology.
Griffin Jw (1976)
Diverse forms of motor neuron diseases.
Rowland Lp (1982)
10.1212/WNL.18.2.101
Spinal muscular atrophy secondary to macroglobulinemia: Reversal of symptoms with chlorambucil therapy
H. Peters (1968)
10.1016/S0140-6736(83)90060-0
EFFECT ON WEAKNESS AND SPASTICITY IN AMYOTROPHIC LATERAL SCLEROSIS OF THYROTROPIN-RELEASING HORMONE
W. Engel (1983)
10.1001/ARCHNEUR.1986.00520090061018
Administration of recombinant human leukocyte alpha 2-interferon in patients with amyotrophic lateral sclerosis.
M. Dalakas (1986)
10.1212/WNL.36.4.511
Familial adult motor neuron disease: amyotrophic lateral sclerosis
D. Mulder (1986)
[Post-radiotherapy anterior horn cell syndrome].
A. Lagueny (1985)
10.1212/WNL.30.5.453
Epidemiology of amyotrophic lateral sclerosis
J. Kurtzke (1980)
10.1212/WNL.30.12.1319
Attempts to demonstrate virus in amyotrophic lateral sclerosis
L. Weiner (1980)
10.1111/j.1600-0404.1985.tb03215.x
Autonomic function in amyotrophic lateral sclerosis: a study of cardiovascular responses
C. Sachs (1985)
Immunological profile of amyotrophic lateral sclerosis patients and their cell-mediated immune responses to viral and CNS antigens.
H. Bartfeld (1982)
10.1126/SCIENCE.3603037
Guam amyotrophic lateral sclerosis-parkinsonism-dementia linked to a plant excitant neurotoxin.
P. Spencer (1987)
10.1002/MUS.880060606
Acetylcholinesterase and ATPases in motor neuron degenerative diseases
C. G. Rasool (1983)
10.1002/ANA.410160114
Nystagmus in motor neuron disease: Clinicopathological study of two cases
M. Kushner (1984)
10.1002/ANA.410030512
Juvenile type of distal and segmental muscular atrophy of upper extremities
I. Sobue (1978)
10.1001/ARCHNEUR.1973.00490280027003
Terminal innervation ratio in neuromuscular disease. II. Disorders of lower motor neuron, peripheral nerve, and muscle.
C. Coërs (1973)
10.1016/0022-510X(75)90166-5
Single fibre electromyography in various processes affecting the anterior horn cell
E. Stålberg (1975)
10.1002/MUS.880080109
Axonal regeneration in wobbler motor neuron disease: Quantitative histologic and axonal transport studies
H. Mitsumoto (1985)
10.1002/ANA.410080612
Amyotrophic lateral sclerosis among chamorro migrants from guam
Ralph M. Garruto (1980)
10.1212/WNL.36.9.1260
Slow resolution of multifocal weakness and fasciculation
D. Chad (1986)
10.1002/MUS.880050203
Virological studies in amyotrophic lateral sclerosis
R. Kascsak (1982)
10.1212/WNL.27.7.692
Amyotrophic lateral sclerosis in dizygotic twins
W. Estrin (1977)
10.1001/ARCHNEUR.1974.00490330050008
Amyotrophic lateral sclerosis. Electrophysiologic study (number of motor units and rate of decay of motor units).
W. Brown (1974)
10.1056/NEJM198307283090416
Amyotrophic lateral sclerosis and pet exposure.
N. Schenkman (1983)
10.1056/NEJM198503143121110
Hypothesis: Interference with Axonal Transport of Neurofilament as a Common Pathogenetic Mechanism in Certain Diseases of the Central Nervous System
Gajdusĕk Dc (1985)
10.1212/WNL.18.1_Part_2.101
Myxoviruses and infections of the nervous system
R. T. Johnson (1968)
10.1002/ANA.410050602
Does a defect of energy metabolism in the nerve fiber underlie axonal degeneration in polyneuropathies?
P. Spencer (1979)
10.1038/307546A0
Suppression of sprouting at the neuromuscular junction by immune sera
M. Gurney (1984)
10.1093/BRAIN/105.4.811
Murine motor neuron disease (the wobbler mouse): degeneration and regeneration of the lower motor neuron.
H. Mitsumoto (1982)
10.1097/00000441-198401000-00008
Computerized Axial Tomography in the Diagnosis and Management of Thyroid and Parathyroid Disorders
M. Blum (1984)
10.1001/ARCHNEUR.1982.00510200049009
Thiamin monophosphate in the CSF of patients with amyotrophic lateral sclerosis.
M. Poloni (1982)
10.1097/00005072-198140010-00004
RNA content and volume of motor neurons in amyotrophic lateral sclerosis. I. The cervical swelling.
T. J. Davidson (1981)
10.1212/WNL.36.2.146
Controlled trial of thyrotropin releasing hormone in amyotrophic lateral sclerosis
M. Brooke (1986)
10.1016/0022-510X(83)90012-6
Increased manganese level in spinal cords of amyotrophic lateral sclerosis determined by radiochemical neutron activation analysis
S. Miyata (1983)
10.1212/WNL.37.8.1339
Motor neuron disease in the United States, 1971 and 1973–1978
M. Leone (1987)
10.1016/0022-510X(82)90117-4
Enzymatic analysis of individual anterior horn cells in amyotrophic lateral sclerosis and Duchenne muscular dystrophy
H. Hayashi (1982)
10.1212/WNL.34.10.1299
Retrograde axoplasmic transport of Adriamycin
T. Yamamoto (1984)
[Negative symptoms and signs of amyotrophic lateral sclerosis. Disturbance of micturition].
T. Hattori (1984)
10.1016/0022-510X(83)90082-5
Chronic asymmetrical spinal muscular atrophy
A. Harding (1983)
Lower motor neuron disease in wild mice caused by indigenous type C virus and search for a similar etiology in human amyotrophic lateral sclerosis.
M. Gardner (1976)
10.1001/ARCHNEUR.1982.00510230007002
Classic amyotrophic lateral sclerosis with dementia.
J. Wikström (1982)
10.1212/WNL.30.1.98
Norepinephrine and gamma‐aminobutyric acid in amyotrophic lateral sclerosis
M. Ziegler (1980)
10.1002/ANA.410140627
Conjugal amyotrophic lateral sclerosis
E. Paolino (1983)
10.1016/0006-8993(82)90439-5
Choline acetyltransferase and substance P-like immuno-reactivity in the human spinal cord: changes in amyotrophic lateral sclerosis
Per-Go¨ran Gillberg (1982)
10.1212/WNL.36.2.273
Gammopathy with proximal motor axonopathy simulating motor neuron disease
G. Parry (1986)
10.1126/SCIENCE.4039466
Circulating autoantibodies to the 200,000-dalton protein of neurofilaments in the serum of healthy individuals.
K. Stefánsson (1985)
10.1212/WNL.11.7.639
A syndrome clinically resembling amyotrophic lateral sclerosis following chronic mercurialism
A. D. Kantarjian (1961)
10.1002/ANA.410190608
N‐acetyl‐β‐hexosaminidase β locus defect and juvenile motor neuron disease: A case study
N. Cashman (1986)
10.1136/jnnp.37.9.1036
Motor neurone disease: the nature of the pathogenic mechanism
D. Mann (1974)
10.1212/WNL.7.2.124
Collateral Regeneration from Residual Motor Nerve Fibers in Amyotrophic Lateral Sclerosis
G. Wohlfart (1957)
10.1111/j.1600-0404.1983.tb04543.x
Amyotrophic lateral sclerosis in Middle‐Finland: an epidemiological study
K. Murros (1983)
10.1001/ARCHNEUR.1982.00510230003001
A new hypothesis of the etiology of amyotrophic lateral sclerosis. The DNA hypothesis.
W. Bradley (1982)
10.1097/00005072-198409000-00001
Fine Structural Observations of Neurofilamentous Changes in Amyotrophic Lateral Sclerosis
A. Hirano (1984)
10.1016/0022-510X(87)90039-6
Thyrotropin-releasing hormone (TRH) in murine motor neuron disease (the wobbler mouse)
W. Kozachuk (1987)
10.1002/MUS.880100603
Recent views on amyotrophic lateral sclerosis with emphasis on electrophysiological studies
W. G. Bradley (1987)
10.1056/NEJM198201213060305
Thyrotropin-releasing hormone.
I. Jackson (1982)
Studies on a murine form of spontaneous lower motor neuron degeneration--the wobbler (wa) mouse.
J. M. Andrews (1974)
10.7326/0003-4819-80-2-221
Xeroderma pigmentosum. An inherited diseases with sun sensitivity, multiple cutaneous neoplasms, and abnormal DNA repair.
J. H. Robbins (1974)
10.1002/ANA.410140304
Morphometric and biochemical studies of peripheral nerves in amyotrophic lateral sclerosis
W. Bradley (1983)
10.1212/WNL.30.9.1011
Neuroelectric blocking activity and plasmapheresis in amyotrophic lateral sclerosis
C. Schauf (1980)
10.1212/WNL.35.1.73
Validity and reliability of a rating scale for the primary torsion dystonias
R. Burke (1985)
10.1016/0014-4886(80)90241-1
Reduced protein synthesis in spinal anterior horn neurons in wobbler mouse mutant
T. Murakami (1980)
10.1016/0022-510X(73)90030-0
Functional compensation of human motor units in health and disease.
W. Brown (1973)
10.1212/WNL.32.2.107
Amyotrophic lateral sclerosis and parkinsonian syndromes in high incidence among the Auyu and Jakai people of West New Guinea
D. Gajdusek (1982)
[Endocrinological investigation in patients with progressive proximal spinal and bulbar muscular atrophy of late onset (Kennedy-Alter-Sung type) (author's transl)].
H. Imai (1980)
10.1001/JAMA.1977.03270530051023
Amyotrophic lateral sclerosis in a high selenium environment.
A. W. Kilness (1977)
Further studies in search of a virus in amyotrophic lateral sclerosis.
Fallis Rj (1982)
10.1016/0022-510X(84)90154-0
Insulin resistance in amyotrophic lateral sclerosis
E. Reyes (1984)
The etiology of amyotrophic lateral sclerosis
Khondkarian Oa (1971)
10.1212/WNL.36.2.152
Amyotrophic lateral sclerosis
H. Mitsumoto (1986)
10.1212/WNL.36.8.1137
Intrathecal administration of natural human nterferon alpha in amyotrophic lateral sclerosis
J. S. Mora (1986)
10.1001/ARCHNEURPSYC.1954.02330060010002
Chronic mercurialism; a cause of the clinical syndrome of amyotrophic lateral sclerosis.
I. Brown (1954)
10.1126/SCIENCE.187.4172.113
THE NERVE GROWTH FACTOR.
R. Levi-Montalcini (1964)
10.1001/ARCHNEUR.1983.04050110070012
Plasmapheresis with immunosuppression in amyotrophic lateral sclerosis.
J. Kelemen (1983)
10.1212/WNL.32.8.896
Amyotrophic lateral sclerosis and paraproteinemia
C. Krieger (1982)
10.1056/NEJM198604103141505
A long-term follow-up study of patients with post-poliomyelitis neuromuscular symptoms.
M. Dalakas (1986)
10.1001/ARCHNEUR.1984.04050170073021
Quantitative axon terminal and end-plate morphology in amyotrophic lateral sclerosis.
E. K. Bjornskov (1984)
10.1126/SCIENCE.81524
Slow axonal transport of neurofilament proteins: impairment of beta,beta'-iminodipropionitrile administration.
J. Griffin (1978)
10.1212/WNL.35.1.106
Essential voice tremor
W. Koller (1985)
Spongiform polioencephalomyelopathy caused by a murine retrovirus. I. Pathogenesis of infection in newborn mice.
B. Brooks (1980)
10.1016/0022-510X(82)90173-3
Degeneration and regeneration of ventral root motor fibers in amyotrophic lateral sclerosis: Morphometric studies of cervical ventral roots
N. Hanyu (1982)
Clinical limits of amyotrophic lateral sclerosis.
Mulder Dw (1982)
10.1136/jnnp.43.1.46
Motor neurone disease and hyperthyroid Graves' disease: a chance association?
J. Mcmenamin (1980)
Prognosis in amyotrophic lateral sclerosis.
Norris Fh (1971)
10.1212/WNL.37.2.335
Motor neuron disease and paraproteinemia
S. Rudnicki (1987)
10.1126/SCIENCE.7112111
Intraneuronal aluminum accumulation in amyotrophic lateral sclerosis and Parkinsonism-dementia of Guam.
D. Perl (1982)
10.1212/WNL.34.8.1079
A double‐blind controlled trial of bovine brain gangliosides in amyotrophic lateral sclerosis
W. G. Bradley (1984)
10.1212/WNL.36.1.7
Amyotrophic lateral sclerosis and parkinsonism‐dementia on Guam
P. Rodgers-Johnson (1986)
10.1212/WNL.36.7.948
Amyotrophic lateral sclerosis
S. Ono (1986)
10.1212/WNL.33.2.254-b
An eye movement disorder in ALS
J. McGlone (1983)
10.1016/0022-510X(85)90095-4
Cytotoxic activity in the plasma of amyotrophic lateral sclerosis (ALS) patients against normal erythrocytes: Quantitative determinations
S. Conradi (1985)
10.1002/ANA.410120312
Neurofibrillary axonal pathology in aluminum intoxication
J. Troncoso (1982)
10.1016/0022-510X(74)90057-4
Neurological manifestations of xeroderma pigmentosum in two siblings.
D. Thrush (1974)
10.1523/JNEUROSCI.04-03-00722.1984
Aluminum effect on slow axonal transport: a novel impairment of neurofilament transport
A. Bizzi (1984)
Adult GM2 gangliosidosis masquerading as slowly progressive muscular atrophy: motor neuron disease phenotype.
K. Jellinger (1982)
10.1212/WNL.32.3.315
Lecithin is not effective in amyotrophic lateral sclerosis
J. Kelemen (1982)
10.1212/WNL.18.9.841
Proximal axonal enlargement in motor neuron disease
S. Carpenter (1968)
10.1097/00005072-197905000-00002
HEREDITARY CANINE SPINAL MUSCULAR ATROPHY
L. Cork (1979)
10.1212/WNL.31.8.1054
Amantadine and guanidine are ineffective in ALS
T. Munsat (1981)
10.1056/NEJM198609113151115
Intraneuronal co-localization of silicon with calcium and aluminum in amyotrophic lateral sclerosis and parkinsonism with dementia of Guam.
R. Garruto (1986)
10.1111/j.1600-0404.1982.tb03078.x
Long‐time penicillamine‐treatment in Amyotrophic Lateral Sclerosis with parallel determination of lead in blood, plasma and urine
S. Conradi (1982)
10.1111/j.1600-0404.1984.tb00851.x
Glucose tolerance in amyotrophic lateral sclerosis
K. Harno (1984)
10.1016/0006-8993(84)91392-1
Thyrotropin-releasing hormone (TRH): Apparent receptor binding in rat spinal cord
C. Prasad (1984)
10.1212/WNL.33.1.120
Jugular foramen syndrome
J. Posner (1983)
10.1002/ANA.410180111
Ganglioside patterns in amyotrophic lateral sclerosis brain regions
M. Rapport (1985)
10.1001/ARCHNEUR.1974.00490340060015
Amyotrophic lateral sclerosis sera applied to cultured motor neurons.
M. Horwich (1974)
10.1111/j.1600-0404.1984.tb07775.x
Increased fragility of erythrocytes from amyotrophic lateral sclerosis (ALS) patients provoked by mechanical stress
L. Ronnevi (1984)
10.1016/0014-4886(80)90006-0
Effects of aging on nerve sprouting and regeneration
A. Pestronk (1980)
10.1111/j.1600-0404.1984.tb00801.x
Neurotoxic and other side effects of high‐dose interferon in amyotrophic lateral sclerosis
M. Färkkilä (1984)
10.1001/ARCHNEUR.1980.00500570078020
Amyotrophic lateral sclerosis associated with thyrotoxicosis.
G. Rosati (1980)
[The relationship between prognosis and sex and age at onset in amyotrophic lateral sclerosis].
E. Mukai (1984)
10.1080/00039896.1968.10665310
Amyotrophic lateral sclerosis and metallic toxins.
R. Currier (1968)
10.1016/0165-5728(83)90009-7
Serum antibodies to neurofilament antigens in patients with neurological and other diseases and in healthy controls
S. Bahmanyar (1983)
10.1093/BRAIN/104.2.217
Amyotrophic lateral sclerosis and its association with dementia, parkinsonism and other neurological disorders: a review.
A. Hudson (1981)
10.1002/ANA.410160604
Familial occurrence of amyotrophic lateral sclerosis, parkinsonism, and dementia
H. P. Schmitt (1984)
10.1212/WNL.37.5.738
Fast axonal transport in amyotrophic lateral sclerosis
A. Breuer (1987)
10.1212/WNL.36.4.573
ALS serum has no effect on three enzymatic activities in cultured human spinal cord neurons
G. Touzeau (1986)
10.1523/JNEUROSCI.05-01-00167.1985
Autoradiographic localization of thyrotropin-releasing hormone receptors in the rat central nervous system
S. Manaker. (1985)
10.1056/NEJM198410113111509
Looking for the cause of amyotrophic lateral sclerosis.
L. Rowland (1984)
10.1212/WNL.35.2.251
Serum C‐reactive protein as detector of pretreated childhood bacterial meningitis
H. Peltola (1985)
10.1016/0143-4179(84)90115-X
Motoneurone excitability during antidromically evoked inhibition after administration of a Thyrotrophin Releasing Hormone (TRH) analogue
K. Clarke (1984)
10.1002/ANA.410110103
Juvenile spinal muscular atrophy: A new hexosaminidase deficiency phenotype
W. Johnson (1982)
10.1001/JAMA.1983.03340050054029
Mercury intoxication simulating amyotrophic lateral sclerosis.
C. R. Adams (1983)
10.1212/WNL.33.3.317
Effects of amyotrophic lateral sclerosis sera on cultured cholinergic neurons
G. Touzeau (1983)
A quantitative assessment of reinnervation in the polyneuropathies.
J. Ballantyne (1982)
[Familial amyotrophic lateral sclerosis with ophthalmoplegia].
Y. Tabuchi (1983)
10.1016/S0140-6736(74)93037-2
CLUSTERING OF AMYOTROPHIC LATERAL SCLEROSIS
FredH. Hochberg (1974)
10.1056/NEJM198110293051813
What does brain thyrotropin-releasing hormone do?
A. Prange (1981)
10.1111/j.1471-4159.1984.tb00939.x
Thyrotropin‐Releasing Hormone Enhances Choline Acetyltransferase and Creatine Kinase in Cultured Spinal Ventral Horn Neurons
K. M. Schmidt-Achert (1984)
Growth factors and motor neurons.
S. Varon (1982)
10.1111/j.1749-6632.1983.tb18126.x
OCCURRENCE OF REDUCED α2‐MACROGLOBULIN AND LOWERED PROTEASE INHIBITING CAPACITY IN PLASMA OF AMYOTROPHIC LATERAL SCLEROSIS PATIENTS a
B. Festoff (1983)
10.1002/ANA.410110418
A benign motor neuron disorder: Delayed cramps and fasciculation after poliomyelitis or myelitis
M. Fetell (1982)
10.1001/JAMA.1978.03280320020010
Amyotrophic lateral sclerosis and low urinary selenium levels.
F. H. Norris (1978)
10.1056/NEJM198508013130511
Isolation of LAV/HTLV-III from a patient with amyotrophic lateral sclerosis.
P. Hoffman (1985)
10.1111/j.1749-6632.1979.tb56554.x
PHARMACOLOGIC THERAPY OF DYSTROPHY IN MAN AND ANIMALS *
T. Munsat (1979)
10.1212/WNL.32.3.306
Conjugal motor neuron disease
D. Chad (1982)
10.1001/ARCHNEUR.1981.00510040046007
Case-control studies of motor neuron disease: association with mechanical injuries.
K. Kondo (1981)
10.1097/00005072-198103000-00010
Base Composition of RNA Obtained from Motor Neurons in Amyotrophic Lateral Sclerosis
T. J. Davidson (1981)
10.1002/ANA.410110515
Macroglobulinemia with peripheral neuropathy simulating motor neuron disease
L. Rowland (1982)
10.1212/WNL.36.1.137-a
Pathologic changes after cyanide poisoning
R. Uitti (1986)
10.1136/bmj.2.6153.1684
Response to penicillamine of lead concentrations in CSF and blood in patients with motor neurone disease.
A. House (1978)
10.1016/0022-510X(85)90110-8
Experimental amyotrophic lateral sclerosis in the Guinea-Pig
W. A. D. H. Jager (1985)
10.1212/WNL.32.8.901
Muscle acid protease activity in amyotrophic lateral sclerosis
J. Antel (1982)
10.1136/jnnp.40.5.464
Preservation of a certain motoneurone group of the sacral cord in amyotrophic lateral sclerosis: its clinical significance.
T. Mannen (1977)



This paper is referenced by
10.1016/0010-440X(90)90039-U
Schizophrenia and amyotrophic lateral sclerosis.
R. Howland (1990)
10.1002/(SICI)1097-4598(199709)20:9<1181::AID-MUS15>3.0.CO;2-W
Amyotrophic lateral sclerosis in Mexico: Validation of two predictive scales
E. Otero-Siliceo (1997)
10.1002/MUS.880130206
Impairment of retrograde axonal transport in wobbler mouse motor neuron disease
H. Mitsumoto (1990)
10.1016/0022-510X(92)90204-X
Focal reductions of cerebral blood flow in amyotrophic lateral sclerosis: A [99mTc]-d,l-HMPAO SPECT study
G. Waldemar (1992)
10.1007/978-1-4471-3787-0_35
Motor Neurone Disease: Experience with Large Multicentre Trials
T. Steiner (2001)
10.1111/j.1471-4159.1989.tb09167.x
Choline Acetyltransferase Activities in Single Spinal Motor Neurons from Patients with Amyotrophic Lateral Sclerosis
T. Kato (1989)
10.1007/BF01734544
Opercular syndrome without opercular lesions: Foix-Chavany-Marie syndrome in progressive supranuclear motor system degeneration
M. Weller (2005)
10.1016/S0022-510X(01)00479-8
Cyclophosphamide attenuates the degenerative changes induced by CSF from patients with amyotrophic lateral sclerosis in the neonatal rat spinal cord
Neelam Shahani (2001)
10.1056/NEJM199210293271809
Case 43-1992
T. Munsat (1992)
10.1016/0888-7543(92)90155-L
Mapping of the motor neuron degeneration (Mnd) gene, a mouse model of amyotrophic lateral sclerosis (ALS).
A. Messer (1992)
10.1016/B978-044450811-9/50034-3
Aluminum as an Experimental Neurotoxicant: The Neuropathology and Neurochemistry
M. J. Strong (2001)
10.1002/ANA.410360205
The effects of ciliary neurotrophic factor on motor dysfunction in wobbler mouse motor neuron disease
H. Mitsumoto (1994)
10.1002/MUS.880130211
Cortical magnetic stimulation in amyotrophic lateral sclerosis
A. Eisen (1990)
10.1016/0304-3940(88)90296-0
A filamentous inclusion body within anterior horn neurones in motor neurone disease defined by immunocytochemical localisation of ubiquitin
J. Lowe (1988)
10.1016/S0378-4274(98)00345-2
Chronic administration of aluminium L-glutamate in young mature rats: effects on iron levels and lipid peroxidation in selected brain areas.
R. Deloncle (1999)
10.1080/713610449
Cell Wall-Deficient (CWD) Bacterial Pathogens: Could Amylotrophic Lateral Sclerosis (ALS) Be Due to One?
A. Koch (2003)
10.1007/978-1-4471-1871-8_5
The Pathology of Motor Neuron Disease
J. Martin (1995)
10.1016/j.freeradbiomed.2013.06.029
Clinical perspective on oxidative stress in sporadic amyotrophic lateral sclerosis.
E. D'Amico (2013)
10.1515/REVNEURO.1996.7.3.187
Tachykinins, Neurotrophism and Neurodegenerative Diseases: A Critical Review on the Possible Role of Tachykinins in the Aetiology of CNS Diseases
R. Barker (1996)
10.1016/S0031-9384(97)00154-6
Effect of Dietary Supplementation with Branched-Chain Amino Acids on Spontaneous Motor Activity and Muscle Function in β,β′-Iminodipropionitrile-treated Rats:A Model for Motorneuropathy
Y. Kitahara (1997)
10.1007/BF02444000
Intravenous immunoglobulin therapy in amyotrophic lateral sclerosis
N. Meucci (2006)
10.18452/14952
Die Trinukleotid-Expansion des Gens für zelluläre Glutathion-Peroxidase bei Patienten mit sporadischer amyotropher Lateralsklerose
Jan Matthias Hille (2003)
10.1002/MUS.880140506
The extent and time course of motoneuron involvement in amyotrophic lateral sclerosis.
Marita Dantes Dr. (1991)
10.1007/BF00194097
Immunological findings in amyotrophic lateral sclerosis
J. Antel (2004)
10.3233/TAD-1996-5202
Demographics of rehabilitation robotics users
C. Stanger (1996)
10.1007/BF00838439
Motor neuron disease and past poliomyelitis
F. Moriwaka (2004)
10.1212/WNL.48.4_Suppl_4.2S
Diagnosis and progression of ALS
H. Mitsumoto (1997)
10.1044/JSHR.3701.28
Physiologic deficits in the orofacial system underlying dysarthria in amyotrophic lateral sclerosis.
S. Langmore (1994)
10.1007/978-1-4899-1447-7_3
Experimental Paradigms of Motor Neuron Degeneration
M. J. Strong (1994)
10.1016/S0149-7634(97)00070-5
Possible Role(s) of Neurokinins in CNS Development and Neurodegenerative or Other Disorders
R. Raffa (1998)
10.1007/BF01277964
Insulin-like growth factor-1 receptors in human spinal cord: changes in amyotrophic lateral sclerosis
A. Adem (2005)
10.1002/MUS.880150215
Amyotrophic lateral sclerosis (ALS): A phylogenetic disease of the corticomotoneuron?
A. Eisen (1992)
See more
Semantic Scholar Logo Some data provided by SemanticScholar